Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Augsburg – page 7

300 clinical trials in Augsburg, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Augsburg at a glance
300
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

300 trials in Augsburg

Open in trial search

Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Angiotensin II
  • Sponsor:Universitaet Muenster

Vulval cancer

Recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:AGO Research GmbH

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AGO Research GmbH

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Schizophrenia

Recruiting

Study on Clemastine and Aerobic Exercise for Improving Cognitive Function in Schizophrenia Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clemastine
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Study of Gilteritinib, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutations Not Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Augsburg

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on breast cancer, lung cancer, and lymphoma treatments. Studies evaluating novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • HR-positive breast cancer treatment evaluation
  • Advanced non-small cell lung cancer therapies
  • Lymphoma and leukemia interventions

Several trials are investigating combination therapies to improve patient outcomes in various cancer types.

02 Dermatology Studies

Comprehensive research into plaque psoriasis and atopic dermatitis, with multiple trials testing new therapeutic agents and preventive approaches.

  • Moderate to severe psoriasis treatments
  • Preventive interventions for atopic dermatitis
  • Long-term safety assessments

Focus on both treatment and prevention strategies for chronic skin conditions.

03 Gastrointestinal Research

Innovative studies addressing ulcerative colitis and gastroparesis, testing novel therapeutic approaches and treatment combinations.

  • Ulcerative colitis treatment optimization
  • Gastroparesis symptom management
  • Biliary tract cancer therapies

Trials aim to improve quality of life and treatment outcomes for patients with chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.